• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lobe Sciences Ltd (CSE: LOBE )

    0.0200 UNCHANGED
    Last Price Updated: 11:29 AM EDT, Oct 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.0200
    Bid (Size) 0.0150 (194,000)
    Ask (Size) 0.0200 (32,000)
    Prev. Close 0.0200
    Today's Range 0.0200 - 0.0200
    52wk Range 0.0150 - 0.0250
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
    From Lobe Sciences, Ltd.
    Via Business Wire
    Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
    From Lobe Sciences, Ltd.
    Via Business Wire

    Performance

    YTD
    N/A
    N/A
    1 Month
    +33.33%
    +33.33%
    3 Month
    N/A
    N/A
    6 Month
    -20.00%
    -20.00%
    1 Year
    N/A
    N/A

    More News

    Read More
    Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
    From Lobe Sciences Ltd
    Via Business Wire
    Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
    Via TheNewswire.com
    Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
    From Lobe Sciences Ltd
    Via Business Wire
    Lobe Sciences Announces Update
    From Lobe Sciences Ltd.
    Via Business Wire
    Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
    From Lobe Sciences Ltd.
    Via Business Wire
    Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
    From Lobe Sciences Ltd.
    Via Business Wire
    Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
    From Lobe Sciences Ltd.
    Via Business Wire
    Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
    From Lobe Sciences Ltd.
    Via Business Wire
    Lobe Sciences Provides Company Review of 2023
    From Lobe Sciences Ltd.
    Via Business Wire
    Lobe Sciences Provides Update on L-130 Clinical Program
    From Lobe Sciences Ltd.
    Via Business Wire
    Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
    From Lobe Sciences Ltd.
    Via Business Wire
    Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
    From Lobe Sciences Ltd.
    Via Business Wire
    Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
    From Lobe Sciences Ltd.
    Via Business Wire
    Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer
    From Lobe Sciences Ltd.
    Via Business Wire
    Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™
    From Lobe Sciences Ltd.
    Via Business Wire
    The Power Play by The Market Herald Releases New Interviews with ARway, Silver Bullet Mines, Galantas Gold, Lobe Sciences, Northstar Gold and Rover Metals Discussing Their Latest News
    Via ACCESSWIRE
    Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
    Via FinancialNewsMedia
    Topics Economy
    Exposures Supply Chain
    Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
    Via FinancialNewsMedia
    Exposures Product Safety
    Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
    Via AB Newswire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lobe Sciences Announces Incorporation of Australian Subsidiary
    Via Newsfile
    Lobe Sciences Announces Closing of Private Placement
    Via Newsfile
    Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
    Via Newsfile
    Topics Cannabis
    Exposures Cannabis
    Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) Featured in Coverage of Planet MicroCap’s Virtual Investor Conference
    Via Investor Brand Network
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.